Lopinavir/ritonavir

Drug Profile

Lopinavir/ritonavir

Alternative Names: ABT-378/r; ABT-378/ritonavir; Aluvia; Kaletra

Latest Information Update: 13 Feb 2017

Price : $50

At a glance

  • Originator Abbott Laboratories
  • Developer Abbott Laboratories; AbbVie; University of Alberta
  • Class Amides; Antiretrovirals; Pyrimidinones; Small molecules; Thiazoles
  • Mechanism of Action HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV infections
  • Phase II Primary biliary cirrhosis

Most Recent Events

  • 30 Nov 2014 Lopinavir/ritonavir licensed to Medicines Patent Pool worldwide
  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
  • 31 Oct 2010 Abbott and Merck complete the PROGRESS phase III trial in HIV infections (Treatment-naive, Combination therapy) in USA, Canada, European Union and Puerto Rico (NCT00711009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top